"Eli Lilly's Bold Move: Direct Sales and the Battle Against Cosmetic Weight Loss"
Eli Lilly has issued a statement discouraging the use of its diabetes drugs Mounjaro and Zepbound for cosmetic weight loss, emphasizing that they are intended for serious medical conditions and should only be prescribed by healthcare professionals. Despite their popularity for weight loss among the general public, including non-obese individuals, experts warn of potential risks and the possibility of weight regain after discontinuation. The company insists on the drugs' use in conjunction with a healthy diet and exercise for approved medical conditions.